First Time Loading...

Novo Nordisk A/S
NYSE:NVO

Watchlist Manager
Novo Nordisk A/S Logo
Novo Nordisk A/S
NYSE:NVO
Watchlist
Price: 122.75 USD -1.43% Market Closed
Updated: Apr 19, 2024

Intrinsic Value

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. [ Read More ]

The intrinsic value of one NVO stock under the Base Case scenario is 88.5 USD. Compared to the current market price of 122.75 USD, Novo Nordisk A/S is Overvalued by 28%.

Key Points:
NVO Intrinsic Value
Base Case
88.5 USD
Overvaluation 28%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Novo Nordisk A/S

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling NVO stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Novo Nordisk A/S

Provide an overview of the primary business activities
of Novo Nordisk A/S.

What unique competitive advantages
does Novo Nordisk A/S hold over its rivals?

What risks and challenges
does Novo Nordisk A/S face in the near future?

Summarize the latest earnings call
of Novo Nordisk A/S.

What significant events have occurred
in Novo Nordisk A/S over the past months?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Novo Nordisk A/S.

Provide P/S
for Novo Nordisk A/S.

Provide P/E
for Novo Nordisk A/S.

Provide P/OCF
for Novo Nordisk A/S.

Provide P/FCFE
for Novo Nordisk A/S.

Provide P/B
for Novo Nordisk A/S.

Provide EV/S
for Novo Nordisk A/S.

Provide EV/GP
for Novo Nordisk A/S.

Provide EV/EBITDA
for Novo Nordisk A/S.

Provide EV/EBIT
for Novo Nordisk A/S.

Provide EV/OCF
for Novo Nordisk A/S.

Provide EV/FCFF
for Novo Nordisk A/S.

Provide EV/IC
for Novo Nordisk A/S.

Show me price targets
for Novo Nordisk A/S made by professional analysts.

What are the Revenue projections
for Novo Nordisk A/S?

How accurate were the past Revenue estimates
for Novo Nordisk A/S?

What are the Net Income projections
for Novo Nordisk A/S?

How accurate were the past Net Income estimates
for Novo Nordisk A/S?

What are the EPS projections
for Novo Nordisk A/S?

How accurate were the past EPS estimates
for Novo Nordisk A/S?

What are the EBIT projections
for Novo Nordisk A/S?

How accurate were the past EBIT estimates
for Novo Nordisk A/S?

Compare the revenue forecasts
for Novo Nordisk A/S with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Novo Nordisk A/S and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Novo Nordisk A/S against its competitors.

Analyze the profit margins
(gross, operating, and net) of Novo Nordisk A/S compared to its peers.

Compare the P/E ratios
of Novo Nordisk A/S against its peers.

Discuss the investment returns and shareholder value creation
comparing Novo Nordisk A/S with its peers.

Analyze the financial leverage
of Novo Nordisk A/S compared to its main competitors.

Show all profitability ratios
for Novo Nordisk A/S.

Provide ROE
for Novo Nordisk A/S.

Provide ROA
for Novo Nordisk A/S.

Provide ROIC
for Novo Nordisk A/S.

Provide ROCE
for Novo Nordisk A/S.

Provide Gross Margin
for Novo Nordisk A/S.

Provide Operating Margin
for Novo Nordisk A/S.

Provide Net Margin
for Novo Nordisk A/S.

Provide FCF Margin
for Novo Nordisk A/S.

Show all solvency ratios
for Novo Nordisk A/S.

Provide D/E Ratio
for Novo Nordisk A/S.

Provide D/A Ratio
for Novo Nordisk A/S.

Provide Interest Coverage Ratio
for Novo Nordisk A/S.

Provide Altman Z-Score Ratio
for Novo Nordisk A/S.

Provide Quick Ratio
for Novo Nordisk A/S.

Provide Current Ratio
for Novo Nordisk A/S.

Provide Cash Ratio
for Novo Nordisk A/S.

What is the historical Revenue growth
over the last 5 years for Novo Nordisk A/S?

What is the historical Net Income growth
over the last 5 years for Novo Nordisk A/S?

What is the current Free Cash Flow
of Novo Nordisk A/S?

Financials

Balance Sheet Decomposition
Novo Nordisk A/S

Current Assets 139.6B
Cash & Short-Term Investments 30.2B
Receivables 75.3B
Other Current Assets 34.2B
Non-Current Assets 174.8B
Long-Term Investments 1.7B
PP&E 91B
Intangibles 60.4B
Other Non-Current Assets 21.8B
Current Liabilities 169.7B
Accounts Payable 25.6B
Other Current Liabilities 144B
Non-Current Liabilities 38.3B
Long-Term Debt 20.5B
Other Non-Current Liabilities 17.7B
Efficiency

Earnings Waterfall
Novo Nordisk A/S

Revenue
232.3B DKK
Cost of Revenue
-35.8B DKK
Gross Profit
196.5B DKK
Operating Expenses
-91.8B DKK
Operating Income
104.7B DKK
Other Expenses
-21B DKK
Net Income
83.7B DKK

Free Cash Flow Analysis
Novo Nordisk A/S

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

NVO Profitability Score
Profitability Due Diligence

Novo Nordisk A/S's profitability score is 86/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROE
Positive Free Cash Flow
Exceptional 3-Year Average ROIC
Positive Gross Profit
86/100
Profitability
Score

Novo Nordisk A/S's profitability score is 86/100. The higher the profitability score, the more profitable the company is.

NVO Solvency Score
Solvency Due Diligence

Novo Nordisk A/S's solvency score is 79/100. The higher the solvency score, the more solvent the company is.

79/100
Solvency
Score

Novo Nordisk A/S's solvency score is 79/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

NVO Price Targets Summary
Novo Nordisk A/S

Wall Street analysts forecast NVO stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for NVO is 133.89 USD with a low forecast of 77.99 USD and a high forecast of 168.28 USD.

Lowest
Price Target
77.99 USD
36% Downside
Average
Price Target
133.89 USD
9% Upside
Highest
Price Target
168.28 USD
37% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Shareholder Return

NOVO B Price
Novo Nordisk A/S

1M 1M
-3%
6M 6M
+26%
1Y 1Y
+54%
3Y 3Y
+308%
5Y 5Y
+519%
10Y 10Y
+932%
Annual Price Range
862.7
52w Low
514.5667
52w High
924.5
Price Metrics
Average Annual Return 36.42%
Standard Deviation of Annual Returns 24.56%
Max Drawdown -7%
Shares Statistics
Market Capitalization 3.8T DKK
Shares Outstanding 4 462 427 800
Percentage of Shares Shorted
N/A

NOVO B Return Decomposition
Main factors of price return

What is price return decomposition?

NVO News

Other Videos

Last Important Events
Novo Nordisk A/S

Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.

All
Positive
Negative

Sentiment Analysis
Novo Nordisk A/S

Today
Last 7 Days 7D
Last 30 Days 30D
Last 90 Days 90D

Company Profile

Novo Nordisk A/S Logo
Novo Nordisk A/S

Country

Denmark

Industry

Pharmaceuticals

Market Cap

3.8T USD

Dividend Yield

1.13%

Description

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. The firm is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The firm operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The firm's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The firm's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The firm also offers Saxenda product to treat obesity. The company offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.

Contact

Bagsvaerd
Novo Alle 1
+4544448888.0
https://www.novonordisk.com/

IPO

1974-05-17

Employees

47 792

Officers

President, CEO & Member of Management Board
Mr. Lars Fruergaard Jorgensen
Executive VP, CFO & Member of the Management Board
Mr. Karsten Munk Knudsen
Executive VP of Product Supply, Quality & IT and Member of the Management Board
Mr. Henrik Ehlers Wulff
Executive VP of Commercial Strategy & Corporate Affairs and Member of the Management Board
Ms. Camilla Sylvest
Executive VP of Development & Member of the Management Board
Dr. Martin Holst Lange
EVP of Research & Early Development, Chief Scientific Officer & Member of the Management Board
Dr. Marcus Schindler Ph.D.
Show More
Executive VP of International Operations & Member of the Management Board
Mr. Maziar Mike Doustdar
Executive VP of North America Operations & Member of Management Board
Mr. Douglas J. Langa
Executive VP, Head of Rare Disease & Member of Management Board
Mr. Ludovic Helfgott
Executive VP of Global People & Organisation and Member of Management Board
Ms. Tania Sabroe
Show Less

See Also

Discover More
What is the Intrinsic Value of one NVO stock?

The intrinsic value of one NVO stock under the Base Case scenario is 88.5 USD.

Is NVO stock undervalued or overvalued?

Compared to the current market price of 122.75 USD, Novo Nordisk A/S is Overvalued by 28%.